About Event
Welcome to the 12th Annual Tumor Models Summit
The Tumor Models Boston Summit stands as the only industry-led meeting uniting pharma and biotech from the East Coast to network and discuss innovations in tumor models.
With a better understanding of phenotype, genotype and tumor microenvironment advancing the development of more translatable models, an industry-wide move to precision oncology requiring more specific genetic models, and better availability of patient-derived and next-generation models improving translatability of studies, it is essential that the industry remains up with the latest and greatest happenings in in vivo and in vitro tumor modelling to improve translatability into the clinic.
The 12th annual event returned to Boston in 2024 and provided a platform for industry experts to share updates on tumor model advancements and demonstrate how they are utilizing these models in drug and screening or for efficacy evaluation and biomarker, ultimately to increase clinical confidence and clinical relevancy.
With an agenda jam-packed with 28+ case studies, here’s what the 2024 event had in store for attendees:
Expert Insights from Industry Leaders: Gain first hand insights from esteemed companies such as Sanofi, AstraZeneca, Takeda, Merck, Abbvie, Amgen and more as they delve into topics including effectively replicating the tumor stroma and fibroblasts using in vivo and in vitro models, exploring in vivo imaging biomarkers for tumor model development and MoA understanding, optimizing patient representation using PDX models and elucidating a in vivo gene therapy approach to reprogram the patients’ immune cells to fight cancer
Networking: Exchange challenges and inspire solutions with leading industry experts across dedicated speed-networking sessions as well as assess the latest technologies from the last 12 months
The Opportunity to Form Meaningful Partnerships: Meet and network with selected CROs, model developers and academics to hear their latest platforms that will optimize your workflows
Who Would You Have Met?
Be part of this growing community next year to support your pipeline acceleration, and develop a novel, safe and efficacious treatments for patients in need!